158 related articles for article (PubMed ID: 21160471)
1. Cancer: Small papillary thyroid cancers--is BRAF of prognostic value?
Soares P; Sobrinho-Simões M
Nat Rev Endocrinol; 2011 Jan; 7(1):9-10. PubMed ID: 21160471
[TBL] [Abstract][Full Text] [Related]
2. BRAF in papillary thyroid carcinoma.
Lanzilotta SG; Grammatica L; Paradiso A; Simone G
Cell Oncol; 2007; 29(4):269-77. PubMed ID: 17641411
[TBL] [Abstract][Full Text] [Related]
3. BRAF Status in Papillary Microcarcinomas of the Thyroid Gland: a Brief Review.
Ieni A; Vita R; Cardia R; Giuffré G; Benvenga S; Tuccari G
Curr Mol Med; 2019; 19(9):665-672. PubMed ID: 31625469
[TBL] [Abstract][Full Text] [Related]
4. A new mechanism of BRAF activation in human thyroid papillary carcinomas.
Fusco A; Viglietto G; Santoro M
J Clin Invest; 2005 Jan; 115(1):20-3. PubMed ID: 15630436
[TBL] [Abstract][Full Text] [Related]
5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
6. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
7. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area.
Kim HJ; Park HK; Byun DW; Suh K; Yoo MH; Min YK; Kim SW; Chung JH
Eur J Nutr; 2018 Mar; 57(2):809-815. PubMed ID: 28258306
[TBL] [Abstract][Full Text] [Related]
8. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
10. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
11. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
12. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
13. [Expression of BRAF and its extracellular signal-regulated kinase 1/2 signal pathway in papillary thyroid cancer].
Yi W; Zhong D; Zou Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 37(9):889-94. PubMed ID: 23000762
[TBL] [Abstract][Full Text] [Related]
14. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
15. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
16. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L
Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
[TBL] [Abstract][Full Text] [Related]
17. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status.
Mussazhanova Z; Matsuda K; Naruke Y; Mitsutake N; Stanojevic B; Rougounovitch T; Saenko V; Suzuki K; Nishihara E; Hirokawa M; Ito M; Nakashima M
Histopathology; 2013 Nov; 63(5):726-34. PubMed ID: 24004175
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the expression levels of BRAF
Tran TV; Dang KX; Pham QH; Nguyen UD; Trinh NTT; Hoang LV; Ho SA; Nguyen BV; Nguyen DT; Trinh DT; Tran DN; Orpana A; Stenman UH; Stenman J; Ho TH
BMC Cancer; 2020 May; 20(1):368. PubMed ID: 32357861
[TBL] [Abstract][Full Text] [Related]
19. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
[TBL] [Abstract][Full Text] [Related]
20. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
